Syndax Pharmaceuticals Inc (NASDAQ: SNDX) on Tuesday, soared 3.96% from the previous trading day, before settling in for the closing price of $18.94. Within the past 52 weeks, SNDX’s price has moved between $13.14 and $25.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 1801.91%. The company achieved an average annual earnings per share of -22.79%. With a float of $79.45 million, this company’s outstanding shares have now reached $84.83 million.
Let’s determine the extent of company efficiency that accounts for 184 employees. In terms of profitability, gross margin is -1005.33%, operating margin of -7135.53%, and the pretax margin is -6543.16%.
Syndax Pharmaceuticals Inc (SNDX) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Syndax Pharmaceuticals Inc is 6.64%, while institutional ownership is 97.22%. The most recent insider transaction that took place on Jun 14 ’24, was worth 25,037. In this transaction Chief Financial Officer of this company bought 1,250 shares at a rate of $20.03, taking the stock ownership to the 52,623 shares.
Syndax Pharmaceuticals Inc (SNDX) Earnings and Forecasts
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -1 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.99) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.99 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -22.79% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.50% during the next five years compared to -0.41% drop over the previous five years of trading.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators
Syndax Pharmaceuticals Inc (SNDX) is currently performing well based on its current performance indicators. A quick ratio of 10.50 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 478.73.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.38, a number that is poised to hit -0.92 in the next quarter and is forecasted to reach -3.14 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)
Looking closely at Syndax Pharmaceuticals Inc (NASDAQ: SNDX), its last 5-days average volume was 0.98 million, which is a drop from its year-to-date volume of 1.05 million. As of the previous 9 days, the stock’s Stochastic %D was 57.90%. Additionally, its Average True Range was 0.72.
During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 30.40%, which indicates a significant decrease from 71.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.81% in the past 14 days, which was lower than the 43.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.05, while its 200-day Moving Average is $20.97. However, in the short run, Syndax Pharmaceuticals Inc’s stock first resistance to watch stands at $20.08. Second resistance stands at $20.46. The third major resistance level sits at $21.13. If the price goes on to break the first support level at $19.03, it is likely to go to the next support level at $18.36. Should the price break the second support level, the third support level stands at $17.98.
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats
Market capitalization of the company is 1.68 billion based on 85,096K outstanding shares. Right now, sales total 0 K and income totals -209,360 K. The company made 3,500 K in profit during its latest quarter, and -68,060 K in sales during its previous quarter.
